Comparative safety and costs of stepping down asthma medications in patients with controlled asthma

Matthew A Rank, Juliette T. Liesinger, Megan E. Branda, Michael R. Gionfriddo, Michael Schatz, Robert S. Zeiger, Nilay D Shah

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Limited data exist regarding outcomes after stepping down asthma medication. Objective: We sought to compare the safety and costs of stepping down asthma controller medications with maintaining current treatment levels in patients with controlled asthma. Methods: Patients with persistent asthma were identified from the US Medical Expenditure Panel Survey years 2000-2010. Each patient had Medical Expenditure Panel Survey data for 2 years, and measurement was divided into 5 periods of 4 to 5 months each. Eligibility for stepping down asthma controller medications included no hospitalizations or emergency department visits for asthma in periods 1 to 3 and no systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3. Steps were defined by type and dose of chronic asthma medication based on current guidelines when comparing period 4 with period 3. The primary outcome of complete asthma control in period 5 was defined as no asthma hospitalizations, emergency department visits, and dispensed systemic corticosteroids and 2 or fewer dispensed rescue inhalers. Multivariable analyses were conducted to assess safety and costs after step down compared with those who maintained the treatment level. Results: Overall, 29.9% of patients meeting the inclusion criteria (n = 4235) were eligible for step down; 89.4% (95% CI, 86.4% to 92.4%) of those who stepped down had preserved asthma control compared with 83.5% (95% CI, 79.9% to 87.0%) of those who were similarly eligible for step down but maintained their treatment level. The average monthly asthma-related cost savings was $34.02/mo (95% CI, $5.42/mo to $61.24/mo) with step down compared with maintenance of the treatment level. Conclusion: Stepping down asthma medications in those whose symptoms were controlled led to similar clinical outcomes at reduced cost compared with those who maintained their current treatment level.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
DOIs
StateAccepted/In press - Apr 2 2015

Fingerprint

Asthma
Safety
Costs and Cost Analysis
Nebulizers and Vaporizers
Health Expenditures
Hospital Emergency Service
Adrenal Cortex Hormones
Hospitalization
Therapeutics
Cost Savings
Guidelines

Keywords

  • Anti-inflammatory agents
  • Antiasthma agents
  • Asthma
  • De-escalate
  • Health services
  • Reduce
  • Step down
  • Taper
  • Withdraw

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. / Rank, Matthew A; Liesinger, Juliette T.; Branda, Megan E.; Gionfriddo, Michael R.; Schatz, Michael; Zeiger, Robert S.; Shah, Nilay D.

In: Journal of Allergy and Clinical Immunology, 02.04.2015.

Research output: Contribution to journalArticle

Rank, Matthew A ; Liesinger, Juliette T. ; Branda, Megan E. ; Gionfriddo, Michael R. ; Schatz, Michael ; Zeiger, Robert S. ; Shah, Nilay D. / Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. In: Journal of Allergy and Clinical Immunology. 2015.
@article{1b502a81440e44d4a1dde80d4a302d98,
title = "Comparative safety and costs of stepping down asthma medications in patients with controlled asthma",
abstract = "Background: Limited data exist regarding outcomes after stepping down asthma medication. Objective: We sought to compare the safety and costs of stepping down asthma controller medications with maintaining current treatment levels in patients with controlled asthma. Methods: Patients with persistent asthma were identified from the US Medical Expenditure Panel Survey years 2000-2010. Each patient had Medical Expenditure Panel Survey data for 2 years, and measurement was divided into 5 periods of 4 to 5 months each. Eligibility for stepping down asthma controller medications included no hospitalizations or emergency department visits for asthma in periods 1 to 3 and no systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3. Steps were defined by type and dose of chronic asthma medication based on current guidelines when comparing period 4 with period 3. The primary outcome of complete asthma control in period 5 was defined as no asthma hospitalizations, emergency department visits, and dispensed systemic corticosteroids and 2 or fewer dispensed rescue inhalers. Multivariable analyses were conducted to assess safety and costs after step down compared with those who maintained the treatment level. Results: Overall, 29.9{\%} of patients meeting the inclusion criteria (n = 4235) were eligible for step down; 89.4{\%} (95{\%} CI, 86.4{\%} to 92.4{\%}) of those who stepped down had preserved asthma control compared with 83.5{\%} (95{\%} CI, 79.9{\%} to 87.0{\%}) of those who were similarly eligible for step down but maintained their treatment level. The average monthly asthma-related cost savings was $34.02/mo (95{\%} CI, $5.42/mo to $61.24/mo) with step down compared with maintenance of the treatment level. Conclusion: Stepping down asthma medications in those whose symptoms were controlled led to similar clinical outcomes at reduced cost compared with those who maintained their current treatment level.",
keywords = "Anti-inflammatory agents, Antiasthma agents, Asthma, De-escalate, Health services, Reduce, Step down, Taper, Withdraw",
author = "Rank, {Matthew A} and Liesinger, {Juliette T.} and Branda, {Megan E.} and Gionfriddo, {Michael R.} and Michael Schatz and Zeiger, {Robert S.} and Shah, {Nilay D}",
year = "2015",
month = "4",
day = "2",
doi = "10.1016/j.jaci.2015.08.035",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Comparative safety and costs of stepping down asthma medications in patients with controlled asthma

AU - Rank, Matthew A

AU - Liesinger, Juliette T.

AU - Branda, Megan E.

AU - Gionfriddo, Michael R.

AU - Schatz, Michael

AU - Zeiger, Robert S.

AU - Shah, Nilay D

PY - 2015/4/2

Y1 - 2015/4/2

N2 - Background: Limited data exist regarding outcomes after stepping down asthma medication. Objective: We sought to compare the safety and costs of stepping down asthma controller medications with maintaining current treatment levels in patients with controlled asthma. Methods: Patients with persistent asthma were identified from the US Medical Expenditure Panel Survey years 2000-2010. Each patient had Medical Expenditure Panel Survey data for 2 years, and measurement was divided into 5 periods of 4 to 5 months each. Eligibility for stepping down asthma controller medications included no hospitalizations or emergency department visits for asthma in periods 1 to 3 and no systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3. Steps were defined by type and dose of chronic asthma medication based on current guidelines when comparing period 4 with period 3. The primary outcome of complete asthma control in period 5 was defined as no asthma hospitalizations, emergency department visits, and dispensed systemic corticosteroids and 2 or fewer dispensed rescue inhalers. Multivariable analyses were conducted to assess safety and costs after step down compared with those who maintained the treatment level. Results: Overall, 29.9% of patients meeting the inclusion criteria (n = 4235) were eligible for step down; 89.4% (95% CI, 86.4% to 92.4%) of those who stepped down had preserved asthma control compared with 83.5% (95% CI, 79.9% to 87.0%) of those who were similarly eligible for step down but maintained their treatment level. The average monthly asthma-related cost savings was $34.02/mo (95% CI, $5.42/mo to $61.24/mo) with step down compared with maintenance of the treatment level. Conclusion: Stepping down asthma medications in those whose symptoms were controlled led to similar clinical outcomes at reduced cost compared with those who maintained their current treatment level.

AB - Background: Limited data exist regarding outcomes after stepping down asthma medication. Objective: We sought to compare the safety and costs of stepping down asthma controller medications with maintaining current treatment levels in patients with controlled asthma. Methods: Patients with persistent asthma were identified from the US Medical Expenditure Panel Survey years 2000-2010. Each patient had Medical Expenditure Panel Survey data for 2 years, and measurement was divided into 5 periods of 4 to 5 months each. Eligibility for stepping down asthma controller medications included no hospitalizations or emergency department visits for asthma in periods 1 to 3 and no systemic corticosteroid and 3 or less rescue inhalers dispensed in periods 2 and 3. Steps were defined by type and dose of chronic asthma medication based on current guidelines when comparing period 4 with period 3. The primary outcome of complete asthma control in period 5 was defined as no asthma hospitalizations, emergency department visits, and dispensed systemic corticosteroids and 2 or fewer dispensed rescue inhalers. Multivariable analyses were conducted to assess safety and costs after step down compared with those who maintained the treatment level. Results: Overall, 29.9% of patients meeting the inclusion criteria (n = 4235) were eligible for step down; 89.4% (95% CI, 86.4% to 92.4%) of those who stepped down had preserved asthma control compared with 83.5% (95% CI, 79.9% to 87.0%) of those who were similarly eligible for step down but maintained their treatment level. The average monthly asthma-related cost savings was $34.02/mo (95% CI, $5.42/mo to $61.24/mo) with step down compared with maintenance of the treatment level. Conclusion: Stepping down asthma medications in those whose symptoms were controlled led to similar clinical outcomes at reduced cost compared with those who maintained their current treatment level.

KW - Anti-inflammatory agents

KW - Antiasthma agents

KW - Asthma

KW - De-escalate

KW - Health services

KW - Reduce

KW - Step down

KW - Taper

KW - Withdraw

UR - http://www.scopus.com/inward/record.url?scp=84951111689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951111689&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2015.08.035

DO - 10.1016/j.jaci.2015.08.035

M3 - Article

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

ER -